← back to search

Yazdan Yazdanpanah

Université Claude Bernard Lyon 1 · FR
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, HIV Research and Treatment, and Hepatitis C virus research.
h-index
80
citations
36,273
works
734
NIH funding
primary concept
Medicine
email

Recent publications

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
The Lancet Respiratory Medicine 2023cited by 123position: middledoi
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
EClinicalMedicine 2023cited by 83position: middledoi
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
The Lancet HIV 2023cited by 68position: middledoi
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Critical Care 2023cited by 47position: middledoi
Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study
Clinical Microbiology and Infection 2023cited by 23position: middledoi
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study
Clinical Microbiology and Infection 2022cited by 190position: middledoi
Screening and vaccination against COVID-19 to minimise school closure: a modelling study
The Lancet Infectious Diseases 2022cited by 95position: middledoi
Breakthrough Infections after Postexposure Vaccination against Mpox
New England Journal of Medicine 2022cited by 67position: middledoi
Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
The Journal of Experimental Medicine 2022cited by 66position: middledoi
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
Journal of Antimicrobial Chemotherapy 2022cited by 48position: middledoi
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers
Nature Communications 2022cited by 30position: middledoi
Contributions and challenges of community pharmacists during the COVID-19 pandemic: a qualitative study
Journal of Pharmaceutical Policy and Practice 2022cited by 30position: middledoi
Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France
BMC Medicine 2022cited by 26position: middledoi
A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 Outbreak
Open Forum Infectious Diseases 2022cited by 25position: middledoi
Myocarditis in monkeypox-infected patients: a case series
Clinical Microbiology and Infection 2022cited by 25position: middledoi
Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1
International Journal of Infectious Diseases 2022cited by 23position: middledoi
Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
Clinical Infectious Diseases 2022cited by 23position: middledoi
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity
Nature Immunology 2021cited by 209position: middledoi
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
iScience 2021cited by 154position: middledoi
Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection
The Journal of Infectious Diseases 2021cited by 152position: middledoi
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Clinical Microbiology and Infection 2021cited by 107position: middledoi
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Open Forum Infectious Diseases 2021cited by 61position: middledoi
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2
Viruses 2021cited by 55position: middledoi
Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France
Eurosurveillance 2021cited by 51position: middledoi
Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis
The Lancet Regional Health - Europe 2021cited by 43position: middledoi
Strengthening capacity for clinical research in sub-Saharan Africa: partnerships and networks
International Journal of Infectious Diseases 2021cited by 41position: middledoi
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019
Clinical Infectious Diseases 2021cited by 40position: middledoi
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients.
2021cited by 36position: contributordoi
COVID-19 vaccines: A race against time
Anaesthesia Critical Care & Pain Medicine 2021cited by 17position: middledoi
Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March–May 2020)
Clinical Microbiology and Infection 2021cited by 15position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

François-Xavier Lescure · Inserm17 papers (2015–2022)Diane Descamps · Assistance Publique – Hôpitaux de Paris15 papers (2012–2023)Jean‐Christophe Lucet · Inserm11 papers (2015–2022)Nathan Peiffer‐Smadja · Inserm11 papers (2017–2022) · 10 papers (2012–2019)Benoît Visseaux · Université Claude Bernard Lyon 19 papers (2012–2023)Nadhira Houhou‐Fidouh · Infection, Anti-microbiens, Modélisation, Evolution7 papers (2016–2022)Jean‐François Timsit · Qualcomm (United Kingdom)7 papers (2016–2023)Pierre‐Yves Boëlle · Inserm6 papers (2014–2022)France Mentré · Inserm6 papers (2020–2022)Arnaud Fontanet · Institut Pasteur6 papers (2014–2022)Anthony Cousien · Institut Pasteur6 papers (2014–2021)Philippe Mathurin · Université Lille Nord de France5 papers (2012–2019)Lila Bouadma · Hôpital Avicenne5 papers (2020–2022)Lila Bouadma · Centre de Recherche Épidémiologie et Statistique5 papers (2015–2021)Éric D’Ortenzio · Inserm5 papers (2017–2021)Vittoria Colizza · Inserm5 papers (2014–2022)Valentine Marie Ferré · Department of Virology5 papers (2021–2023)Jade Ghosn · Délégation Paris 55 papers (2020–2022)Bruno Lina · Centre International de Recherche en Infectiologie5 papers (2020–2022)